Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 213 for your search:
Cancer Type/Condition:
Chronic myelogenous leukemia (CML)
Stage/Subtype:
blastic phase
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Intrabone Cord Blood Transplantation
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
TPH/SCU-IMed 01/08
, NCT00838019
2.
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
3.
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Phase:
Phase III, Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
Levosta-CBF-02/04
, NCT00215007
4.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
5.
Unrelated Double Umbilical Cord Blood Units Transplantation
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
1 to 50
Sponsor:
Other
Protocol IDs:
HORCSCT-0902
, NCT01015742
6.
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-Risk Haematology Patients
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
55/05
, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
7.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
8.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
9.
Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CAMN107A2405
, NCT00760877
10.
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CAMN107AMX01
, NCT00905593
11.
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
12.
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-05011-L
, OHSU-210, NCT00245037
13.
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
55 and over
Sponsor:
Other
Protocol IDs:
191199-HMO-CTIL
, NCT00162513
14.
Donor Natural Killer Cell Infusion in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
UMN-2004LS042
, UMN-MT2003-23, UMN-IRB-0405M60481, NCT00303667
15.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
16.
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
2005-0508
, NCT00402558
17.
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 55
Sponsor:
NCI
Protocol IDs:
MSKCC-06125
, NCT00423514
18.
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04U.115
, NCT00429416
19.
Busulfan, Etoposide, Intensity-Modulated Radiation Therapy, and Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI
Protocol IDs:
CHNMC-05013
, 05013, NCT00540995
20.
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AT9283/0002
, 2006-0177, NCT00522990
21.
Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Approved-not yet active
Age:
18 to 55
Sponsor:
Other
Protocol IDs:
ApoCell-I-IIa
, NCT00524784
22.
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
50 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1981.00
, 6508, NCT00555048
23.
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ITL-001-HMC
, NCT00558675
24.
Monoclonal Antibody Therapy, Fludarabine, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
25.
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
25223
, PSU25223, NCT00626626
Select All on Page
1
Help with Results
